Literature DB >> 27365459

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.

Santosha Vardhana1, Anas Younes2.   

Abstract

Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a dense immune microenvironment. However, the role of the immune microenvironment, particularly T and B cells, in either promoting or restricting Classical Hodgkin lymphoma growth remains undefined. Recent dramatic clinical responses seen using monoclonal antibodies against PD-1, a cell surface receptor whose primary function is to restrict T cell activation, have reignited questions regarding the function of the adaptive immune system in classical Hodgkin lymphoma. This review summarizes what is known regarding T cells, B cells, and immune checkpoints in classical Hodgkin lymphoma. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27365459      PMCID: PMC5004458          DOI: 10.3324/haematol.2015.132761

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  124 in total

1.  Acute infectious mononucleosis and Hodgkin's disease occurring simultaneously in the same patient.

Authors:  F C MASSEY; L L LANE; J E INBRIGLIA
Journal:  J Am Med Assoc       Date:  1953-03-21

2.  On some Morbid Appearances of the Absorbent Glands and Spleen.

Authors: 
Journal:  Med Chir Trans       Date:  1832

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

Review 5.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

6.  Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Authors:  Anas Younes; Anna Sureda; Dina Ben-Yehuda; Pier Luigi Zinzani; Tee-Chuan Ong; H Miles Prince; Simon J Harrison; Mark Kirschbaum; Patrick Johnston; Jennifer Gallagher; Christophe Le Corre; Angela Shen; Andreas Engert
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

7.  Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells.

Authors:  Nir Yogev; Friederike Frommer; Dominika Lukas; Kordula Kautz-Neu; Khalad Karram; Daniele Ielo; Esther von Stebut; Hans-Christian Probst; Maries van den Broek; Dieter Riethmacher; Tal Birnberg; Thomas Blank; Boris Reizis; Thomas Korn; Heinz Wiendl; Steffen Jung; Marco Prinz; Florian C Kurschus; Ari Waisman
Journal:  Immunity       Date:  2012-08-16       Impact factor: 31.745

8.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

9.  Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Ranjana H Advani; Sandra J Horning; Richard T Hoppe; Sarah Daadi; John Allen; Yasodha Natkunam; Nancy L Bartlett
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

10.  Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.

Authors:  Roberto Bellucci; Allison Martin; Davide Bommarito; Kathy Wang; Steen H Hansen; Gordon J Freeman; Jerome Ritz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

View more
  42 in total

1.  High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome.

Authors:  Peter Hollander; Peter Kamper; Karin Ekstrom Smedby; Gunilla Enblad; Maja Ludvigsen; Julie Mortensen; Rose-Marie Amini; Stephen Hamilton-Dutoit; Francesco d'Amore; Daniel Molin; Ingrid Glimelius
Journal:  Blood Adv       Date:  2017-08-08

Review 2.  Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.

Authors:  Justine M Kahn; Nmazuo W Ozuah; Kieron Dunleavy; Tara O Henderson; Kara Kelly; Ann LaCasce
Journal:  Blood Adv       Date:  2017-10-10

3.  Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma.

Authors:  O Jimenez; S Colli; M Garcia Lombardi; M V Preciado; E De Matteo; P Chabay
Journal:  Cancer Immunol Immunother       Date:  2020-11-12       Impact factor: 6.968

4.  Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease.

Authors:  Alessandro Pileri; Claudio Agostinelli; Maurizio Sessa; Pietro Quaglino; Marco Santucci; Carlo Tomasini; Vieri Grandi; Paolo Fava; Chiara Astrua; Simona Righi; Annalisa Patrizi; Stefano A Pileri; Nicola Pimpinelli
Journal:  Virchows Arch       Date:  2017-03-20       Impact factor: 4.064

Review 5.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

6.  Indolent T cell lymphoproliferative disorder of the gastrointestinal tract: an uncommon case with lymph node involvement and the classic Hodgkin's lymphoma.

Authors:  Jie Wu; Long-Guang Li; Xiang-Yan Zhang; Li-Li Wang; Li Zhang; Yu-Jing Xiao; Xiao-Ming Xing; Dong-Liang Lin
Journal:  J Gastrointest Oncol       Date:  2020-08

Review 7.  Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.

Authors:  Santosha Vardhana; Kara Cicero; Moises J Velez; Craig H Moskowitz
Journal:  Oncologist       Date:  2018-08-06

8.  Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma.

Authors:  Meret Henry; Steven Buck; Süreyya Savaşan
Journal:  Pediatr Blood Cancer       Date:  2018-07-15       Impact factor: 3.167

Review 9.  AYA Considerations for Aggressive Lymphomas.

Authors:  Gabriela Llaurador; Lisa Giulino-Roth
Journal:  Curr Hematol Malig Rep       Date:  2021-03-16       Impact factor: 3.952

Review 10.  Immunotherapy in the treatment of lymphoma.

Authors:  Lazar S Popovic; Gorana Matovina-Brko; Maja Popovic; Milica Popovic; Ana Cvetanovic; Ivan Nikolic; Biljana Kukic; Dragana Petrovic
Journal:  World J Stem Cells       Date:  2021-06-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.